| Literature DB >> 33492309 |
Sara Falck-Jones1, Sindhu Vangeti1, Meng Yu1, Ryan Falck-Jones2,3, Alberto Cagigi1, Isabella Badolati1, Björn Österberg1, Maximilian Julius Lautenbach4, Eric Åhlberg1, Ang Lin1,5, Rico Lepzien1, Inga Szurgot1, Klara Lenart1, Fredrika Hellgren1, Holden Maecker6, Jörgen Sälde7, Jan Albert8,9, Niclas Johansson4,10, Max Bell2,3, Karin Loré1, Anna Färnert4,10, Anna Smed-Sörensen1.
Abstract
The immunopathology of coronavirus disease 2019 (COVID-19) remains enigmatic, causing immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor cells (M-MDSCs) are T cell suppressors that expand in inflammatory conditions, but their role in acute respiratory infections remains unclear. We studied the blood and airways of patients with COVID-19 across disease severities at multiple time points. M-MDSC frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of patients with COVID-19 compared with healthy controls. M-MDSCs isolated from patients with COVID-19 suppressed T cell proliferation and IFN-γ production partly via an arginase 1-dependent (Arg-1-dependent) mechanism. Furthermore, patients showed increased Arg-1 and IL-6 plasma levels. Patients with COVID-19 had fewer T cells and downregulated expression of the CD3ζ chain. Ordinal regression showed that early M-MDSC frequency predicted subsequent disease severity. In conclusion, M-MDSCs expanded in the blood of patients with COVID-19, suppressed T cells, and were strongly associated with disease severity, indicating a role for M-MDSCs in the dysregulated COVID-19 immune response.Entities:
Keywords: COVID-19; Immunology; Innate immunity
Mesh:
Substances:
Year: 2021 PMID: 33492309 PMCID: PMC7954608 DOI: 10.1172/JCI144734
Source DB: PubMed Journal: J Clin Invest ISSN: 0021-9738 Impact factor: 14.808